These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24595013)

  • 1. No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.
    Söderberg MM; Molden E; Dahl ML
    Pharmacogenet Genomics; 2014 May; 24(5):272-5. PubMed ID: 24595013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.
    Bigos KL; Bies RR; Pollock BG; Lowy JJ; Zhang F; Weinberger DR
    Mol Psychiatry; 2011 Jun; 16(6):620-5. PubMed ID: 21519338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.
    Stone A; Ratnasinghe LD; Emerson GL; Modali R; Lehman T; Runnells G; Carroll A; Carter W; Barnhart S; Rasheed AA; Greene G; Johnson DE; Ambrosone CB; Kadlubar FF; Lang NP
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1257-61. PubMed ID: 15894682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.
    Söderberg MM; Haslemo T; Molden E; Dahl ML
    Pharmacogenet Genomics; 2013 May; 23(5):279-85. PubMed ID: 23492908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of the antipsychotic drug olanzapine by CYP3A43.
    Zhao J; Machalz D; Liu S; Wolf CA; Wolber G; Parr MK; Bureik M
    Xenobiotica; 2022 Apr; 52(4):413-425. PubMed ID: 35582917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
    Czerwensky F; Leucht S; Steimer W
    Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in CYP3A43 is associated with response to antipsychotic medication.
    Brandl EJ; Chowdhury NI; Tiwari AK; Lett TA; Meltzer HY; Kennedy JL; Müller DJ
    J Neural Transm (Vienna); 2015 Jan; 122(1):29-34. PubMed ID: 25150845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.
    Söderberg MM; Haslemo T; Molden E; Dahl ML
    Pharmacogenomics J; 2013 Dec; 13(6):544-50. PubMed ID: 23147717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.
    Tiwari AK; Brandl EJ; Weber C; Likhodi O; Zai CC; Hahn MK; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
    J Clin Psychopharmacol; 2013 Feb; 33(1):11-7. PubMed ID: 23277265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
    BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
    Ding J; Zhang Y; Zhang Y; Yang L; Zhang S; Cui X; Meng Z; Li Y; Xing H
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):552-559. PubMed ID: 36286707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America.
    Degenhardt EK; Tamayo JM; Jamal HH; Gatz J; Tohen M; Durell TM
    Int Clin Psychopharmacol; 2011 May; 26(3):141-5. PubMed ID: 21164352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.
    Haslemo T; Loryan I; Ueda N; Mannheimer B; Bertilsson L; Ingelman-Sundberg M; Molden E; Eliasson E
    Clin Pharmacol Ther; 2012 Aug; 92(2):221-7. PubMed ID: 22713701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.
    Citrome L; Stauffer VL; Chen L; Kinon BJ; Kurtz DL; Jacobson JG; Bergstrom RF
    J Clin Psychopharmacol; 2009 Jun; 29(3):278-83. PubMed ID: 19440083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
    Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
    Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.
    Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
    Eur J Clin Pharmacol; 2010 May; 66(5):465-74. PubMed ID: 20143052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.